June 1, 2012, New York, NY—Scientists from the Ludwig Institute for Cancer Research (LICR) will share research findings from more than a dozen studies both as posters and as part of the published proceedings during the Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place June 1-5 at the McCormick Place in Chicago, Ill.
“Since its inception, the Ludwig Institute has been committed to translating promising discoveries from its basic research program into the clinic and eventually into novel therapies for cancer patients,” said Andrew Simpson, Ph.D., Scientific Director for the Ludwig Institute for Cancer Research. “Research presented at ASCO by our scientists helps advance the scientific dialogue, which we hope will ultimately lead to new cancer treatments.”
Institute abstracts to be presented during poster sessions at the ASCO annual meeting include:
• Role of cytokine-induced plasticity in melanoma on invasive, therapy-resistant cells that express EMT-related genes and pathways. General poster session on melanoma and skin cancers: June 3, from 8:00 AM to 12:00 PM, McCormick S Hall A2, Abstract No. 8542.
• Phase II study of the anti-ganglioside GD3 mouse/human chimeric antibody KW2871 combined with high dose interferon-a2b in patients with metastatic melanoma. General poster session on melanoma and skin cancers: June 3, 8:00 AM to 12:00 PM, McCormick S Hall A2, Abstract No. 8547.
• Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. General poster session on Developmental Therapeutics – Clinical Pharmacology and Immunotherapy: June 4, 8:00 AM to 12:00 PM, McCormick S Hall A2, Abstract No. 2589.
• Pilot study of MAGE-A3 protein vaccination and autologous stem cell transplantation (autoSCT) as consolidation therapy for multiple myeloma (MM). General poster session on Lymphoma and Plasma Cell Disorders: June 4, 1:15 PM to 5:15 PM, McCormick S Hall A2, Abstract No. TPS8111.
• Circulating melanoma cells isolated from clinical blood samples and characterized by full-length mRNA sequencing at single-cell level. General poster session on Tumor Biology: June 4, 1:15 PM to 5:15 PM, McCormick S Hall A2, Abstract No. 10539.
• Analysis of PTEN in patients with advanced colorectal cancer (CRC) receiving capecitabine alone or in combination with bevacizumab with or without mitomycin C in the phase III AGITG MAX trial. General poster session on Gastrointestinal Cancer: June 4, 8:00 AM to 12:00 PM, McCormick S Hall A2, Abstract No. 3534.
• Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment. General poster session on Developmental Therapeutics, Experimental Therapeutics: June 4, 8:00 AM to 12:00 PM, McCormick S Hall A2, Abstract No. 3068.
• Clinicopathologic and molecular associations of PIK3CA and PTEN mutation in colorectal cancer. General poster session on Developmental Therapeutics, Experimental Therapeutics: June 4, 8:00 AM to 12:00 PM, McCormick S Hall A2, Abstract No. 3623.
About the Ludwig Institute for Cancer Research
LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research.